NCT03202147View on ClinicalTrials.gov

Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Ischemic StrokePost-stroke Cognitive Impairment

Interventions

DRUG

Cromolyn

Active capsules for inhalation.

OTHER

Placebo

Non-active capsules for inhalation.

Sponsors

Lead Sponsor

AZTherapies, Inc.

All Listed Sponsors

lead

AZTherapies, Inc.

INDUSTRY